Clinical trial
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00028028 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00028028 |
|---|---|
| Title | CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
| Official title | A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients With Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease After Induction Chemotherapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, pharmacological study, laboratory biomarker analysis |
| Enrollment | 80 |
| Start date | Feb 1, 2002 |
| Primary completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: